The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Boĭko É.V.

Kafedra oftal'mologii Voenno-meditsinskoĭ akademii im. S.M. Kirova, Sankt-Peterburg

Churashov S.V.

Kafedra oftal'mologii Voenno-meditsinskoĭ akademii im. S.M. Kirova, Sankt-Peterburg

Kamilova T.A.

Kafedra oftal'mologii Voenno-meditsinskoĭ akademii im. S.M. Kirova, Sankt-Peterburg

Molecular genetic basis of age-related macular degeneration

Authors:

Boĭko É.V., Churashov S.V., Kamilova T.A.

More about the authors

Journal: Russian Annals of Ophthalmology. 2013;129(2): 81‑85

Read: 1394 times

Download PDF (RU)
Contact the author
Table of contents

MOLECULAR GENETIC BASIS OF AGE-RELATED MACULAR DEGENERATION
MOLECULAR GENETIC BASIS OF AGE-RELATED MACULAR DEGENERATION

To cite this article:

Boĭko ÉV, Churashov SV, Kamilova TA. Molecular genetic basis of age-related macular degeneration. Russian Annals of Ophthalmology. 2013;129(2):81‑85. (In Russ.)

Подписка 2026 Вестник офтальмологии (Russian Annals of Ophthalmology)
 
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Mana­gement of patients with treatment-resistant neovascular age-related macu­lar dege­neration. Russian Annals of Ophthalmology. 2024;(6):63-68
Neuroprotective therapy for age-related macu­lar dege­neration. Russian Annals of Ophthalmology. 2024;(6):152-158
Arti­ficial inte­lligence in asse­ssment of indi­vidual risks of age-related macu­lar dege­neration progression. Russian Annals of Ophthalmology. 2025;(2):123-128
Chro­nic inflammation in case of obesity-associated diseases. Russian Journal of Preventive Medi­cine. 2025;(1):115-121
Pote­ntial and prospects of the astragaloside IV use for age-associated diseases prevention. Russian Journal of Preventive Medi­cine. 2025;(7):94-99
Eculizumab in the treatment of neuromyelitis optica spectrum diso­rder. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):60-65
Abstract:

Visual loss due to age-related macular degeneration (AMD) is caused by one or both forms of advanced disease: "wet" (neovascular) or "dry" (geographic atrophy). Immune system plays a central role in pathogenesis and progression of both AMD forms. Main genetic polymorphisms associated with risk of AMD development and progression were found to be genes that regulate inflammation especially in complement factor H gen (1q31 locus) and 10q26 locus (PLEKHA1/ARMS2/HTRA1). Association of response to treatment and genotype was shown in patients with AMD. Complete characterization of both common and rare alleles that influence AMD risk is necessary for accurate determination of individual genetic risk as well as identification of new targets for therapeutic intervention.

Keywords:

age-related macular degeneration
polymorphism
chronic inflammation
complement
extracellular matrix

Authors:

Boĭko É.V.

Kafedra oftal'mologii Voenno-meditsinskoĭ akademii im. S.M. Kirova, Sankt-Peterburg

Churashov S.V.

Kafedra oftal'mologii Voenno-meditsinskoĭ akademii im. S.M. Kirova, Sankt-Peterburg

Kamilova T.A.

Kafedra oftal'mologii Voenno-meditsinskoĭ akademii im. S.M. Kirova, Sankt-Peterburg

Close metadata

References:

  1. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001; 119: 10: 1417-1436.
  2. Allikmets R., Bergen A., Dean M., Guymer R.H., Hageman G.S., Ksaver C.C., Stefansson K. et al. Geographic atrophy in age-related macular degeneration and TLR3. N Engl J Med 2009; 360: 21: 2252-2254.
  3. Anderson D.H., Radeke M.J., Gallo N.B., Chapin E.A., Johnson P.T., Curletti C.R., Hancox L.S. et al. The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited. Prog Retin Eye Res 2010; 29: 2: 95-112.
  4. AREDS Research Group. Change in area of geographic atrophy in the Age-Related Eye Disease Study: AREDS report number 26. Arch Ophthalmol 2009; 127: 9: 1168-1174.
  5. Bojanowski C.M. An apolipoprotein E variant may protect against age-related macular degeneration through cytokine regulation. Environ Mol Mutagen 2006; 47: 8: 594-602.
  6. Boon C.J., van de Kar N.C., Klevering B.J., Keunen J.E., Cremens F.P., Klaver C.C., Hoyng C.B. et al. The spectrum of phenotypes caused by variants in the CFH gene. Mol Immunol 2009; 46: 8-9: 1573-1594.
  7. Byeon S.H., Lee S.C., Choi S.H., Lee H.K., Lee J.H., Chu Y.K., Kwon O.W. et al. Vascular endothelial growth factor as an autocrine survival factor for retinal pigment epithelial cells under oxidative stress via the VEGF-R2/PI3K/Akt. Invest Ophthalmol Vis Sci 2010; 51: 2: 1190-1197.
  8. Chen W. Meta-analysis of the association of the HTRA1 polymorphisms with the risk of age-related macular degeneration. Exp Eye Res 2009; 89: 3: 292-300.
  9. De Cordoba S.R., de Jorge E.G. Translational mini-review series on complement factor H: genetics and disease associations of human complement factor H. Clin Exp Immunol 2008; 151: 1: 1-13.
  10. DeAngelis M.M., Silveira A.C., Carr E.A., Kim I.K. Genetics of age-related macular degeneration: current concepts, future directions. Semin Ophthalmol 2011; 26: 3: 77-93.
  11. Despriet D.D. Complement component C3 and risk of age-related macular degeneration. Ophthalmology 2009; 116: 3: 474-480.
  12. Feng X. Complement factor H Y402H and C-reactive protein polymorphism and photodynamic therapy response in age-related macular degeneration. Ophthalmology 2009; 116: 10: 1908-1912.
  13. Fritsche L.G. Age-related macular degeneration is associated with an unstable ARMS2 (LOC387715) mRNA. Nat Genet 2008; 40: 7: 892-896.
  14. Immonen I. Vascular endothelial growth factor gene variation and the response to photodynamic therapy in age-related macular degeneration. Ophthalmology 2010; 117: 1: 103-108.
  15. Jonas J.B. Monocyte chemoattractant protein 1, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1 in exudative age-related macular degeneration. Arch Ophthalmol 2010; 128: 10: 1281-1286.
  16. Jozsi M., Zipfel P.F. Factor H family proteins and human diseases. Trends Immunol 2008; 29: 8: 380-387.
  17. Katta S. The molecular genetic basis of age-related macular degeneration: an overview. J Genet 2009; 88: 4: 424-449.
  18. Klein M.L. Progression of geographic atrophy and genotype in age-related macular degeneration. Ophthalmology 2010; 117: 10: 1554-1559.
  19. Kondo N., Bessho H., Honda S., Negi A. Complement factor H Y402H variant and risk of age-related macular degeneration in Asians: a systematic review and meta-analysis. Ophthalmology 2011; 118: 2: 339-344.
  20. Kortvely E. ARMS2 is a constituent of the extracellular matrix providing a link between familial and sporadic age-related macular degenerations. Invest Ophthalmol Vis Sci 2010; 51: 1: 79-88.
  21. Leveziel N., Souied E.H., Richard F., Barbu V., Zourdani A., Morineau G., Zerbib J. PLEKHA1-LOC387715-HTRA1 polymorphisms and exudative age-related macular degeneration in the French population. Mol Vis 2007; 13: 2153-2159.
  22. Liutkeviciene R. Factors determining age-related macular degeneration: a current view. Medicina (Kaunas) 2010; 46: 2: 89-94.
  23. Mattes D., Haas A., Renner W., Steinbrugger I., El-Shabrawi Y., Wedrich A., Werner C. et al. Analysis of three pigment epithelium-derived factor gene polymorphisms in patients with exudative age-related macular degeneration. Mol Vis 2009; 15: 343-348.
  24. Nakai K. Dendritic cells augment choroidal neovascularization. Invest Ophthalmol Vis Sci 2008; 49: 8: 3666-3670.
  25. Nakata I., Yamashiro K., Nakanishi H., Tsujikawa A., Otani A., Yoshimura N. VEGF gene polymorphism and response to intravitreal bevacizumab and triple therapy in age-related macular degeneration. Jpn J Ophthalmol 2011; 55: 5: 435-443.
  26. Nischler C., Oberkofler H., Ortner C., Paikl D., Riha W., Lang N., Ratsch W., Egger S.F. Complement factor H Y402H gene polymorphism and response to intravitreal bevacizumab in exudative age-related macular degeneration. Acta Ophthalmol 2011; 89: 4: e344-349.
  27. Parmeggiani F., Gemmati D., Costagliola C., Cemeraro F., Perri P., D'Angelo S., Romano M.R. et al. Genetic predictors of response to photodynamic therapy. Mol Diagn Ther 2011; 15: 4: 195-210.
  28. Qazi Y., Maddula S., Ambati B.K. Mediators of ocular angiogenesis. J Genet 2009; 88: 4: 495-515.
  29. Scholl H.P.N. Systemic complement activation in age related macular degeneration. PLoS ONE 2008; 3: 7: e2593.
  30. Seddon J.M. Association of CFH Y402H and LOC387715 A69S with progression of age-related macular degeneration. JAMA 2007; 297: 16: 1793-1800.
  31. Shastry B.S. Genetic diversity and medicinal drug response in eye care. Graefes Arch Clin Exp Ophthalmol 2010; 248: 8: 1057-1061.
  32. Sobrin L., Reynolds R., Fagerness J., Leveziel N. ARMS2/HTRA1 locus can confer differential susceptibility to the advanced subtypes of age-related macular degeneration. Am J Ophthalmol 2011; 151: 2: 345-352.
  33. Tang N.P. HTRA1 promoter polymorphism and risk of age-related macular degeneration: a meta-analysis. Ann Epidemiol 2009; 19: 10: 740-745.
  34. Telander D.G. Inflammation and age-related macular degeneration (AMD). Semin Ophthalmology 2011; 26: 3: 192-197.
  35. Yang Z. Toll-like receptor 3 and geographic atrophy in age-related macular degeneration. N Engl J Med 2008; 359: 14: 1456-1463.
  36. Yates J.R. Complement C3 variant and the risk of age related macular degeneration. N Engl J Med 2007; 357: 6: 553-561.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.